La bourse ferme dans 1 h 19 min

Genfit SA (GNFT.PA)

Paris - Paris Prix différé. Devise en EUR
Ajouter à la liste dynamique
4,2520-0,0460 (-1,07 %)
À partir de 3:54PM CET. Marché ouvert.
Plein écran
Clôture précédente4,2980
Ouverture4,3560
OffreS.O. x S.O.
VenteS.O. x S.O.
Var. jour4,2300 - 4,4700
Sur 52 semaines3,0220 - 20,9600
Volume322 771
Volume moyen764 781
Cap. boursière164,978M
Bêta (mensuel sur 5 ans)1,19
Rapport P/E (sur 12 mois)S.O.
BPA (sur 12 mois)-1,6420
Date de bénéfices30 sept. 2020
Dividende et rendement à termeS.O. (S.O.)
Date ex-dividendeS.O.
Objectif sur 1 an63,89
  • Globe Newswire

    GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

    Approval by 98.5% of shareholders (quorum 23.36%) and by 100% of bondholders (quorum 70.88%) that voted€85.7 million convertible debt will be cancelled by spending only €47.48 million following buyback settlement operations to take place this weekMaturity extended to 2025, allowing GENFIT to implement its new corporate strategy Lille, France; Cambridge, MA; January 25, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announced the results of the shareholders’ vote at the Extraordinary Shareholders Meeting which took place on second convening this Monday, January 25, 2021 at 2:30pm (Paris time) (the “Extraordinary Shareholders Meeting”) and the voting results of the holders of the convertible bonds issued by the Company on October 16, 2017 (the “OCEANEs”) at the Bondholders Meeting which took place this Monday, January 25 2021 at 5:30pm (the “Bondholders Meeting”.) All resolutions proposed by the Board of Directors at both Meetings were approved with more than 98.5% of votes at the Extraordinary Shareholders Meeting and 100% of votes at the Bondholders Meeting. The Company can therefore move forward with the partial buyback of 2,895,260 OCEANEs that certain bondholders have agreed to sell to the Company, at a price of €16.40 (including accrued interest of €0.30) (of 6,081,081 OCEANEs initially issued and currently outstanding) amounting to a nominal amount of €85,699,696 euros, or 47.6% of outstanding OCEANEs (€179,999,997.60 nominal amount) for €47.48 million (the “Buyback”). The buyback settlement operations are expected to occur by January 29, 2021. The repurchased OCEANEs will be canceled by the Company. Pascal Prigent, CEO of GENFIT commented: “We would like to thank all of our shareholders and bondholders for their support throughout this process that today approves the amendment of the terms of the OCEANEs, and which will be completed this week with the buyback. As a result, GENFIT will cancel approximately 50% of its convertible bond debt, equalling approximately €85.7 million, by spending only €47.48 million for the buyback. We have also managed to extend the maturity of the remaining OCEANEs to end of 2025, which should give us more flexibility to maximize the opportunities to promote and value data from our ELATIVE™ Phase 3 clinial trial in PBC, should they be positive early 2023. Our teams are looking to the future and determined to make 2021 our come back year: now that the financial constraint is lifted, we are back to our full ability to implement our new strategy”. Extraordinary Shareholders Meeting All resolutions were adopted with a majority of more than 98.5% of votes, as per the Board of Directors’ recommendations. 9,068,366 shares were recorded out of a total of 38,813,943 shares with a voting right out of a total of 38,858,617 shares, corresponding to a quorum of 23.36%. The result of the vote resolution by resolution is available of the Company website in the Investor & Media section of the website https://ir.genfit.com/financial-information/shareholders-meeting. A recording of the Extraordinary Shareholders Meeting is available on our investors website https://ir.genfit.com/, in the “Events” section and on the “Shareholders Meeting” page, under the “Financials” section. Bondholders Meeting All resolutions were adopted with 100% of votes, as per the Board of Directors’ recommendations. 4,310,607 OCEANEs were recorded out of a total of 6,081,081 OCEANEs, corresponding to a quorum of 70.88%. The result of the vote resolution by resolution is available of the Company website in the Investor & Media section of the website https://ir.genfit.com/financial-information/shareholders-meeting. A recording of the Bondholders Meeting is available on our investors website https://ir.genfit.com/, in the “Events” section and on the “Shareholders Meeting” page, under the “Financials” section. ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com FORWARD LOOKING STATEMENTS This press release is not an advertisement and does not constitute a prospectus for the purpose of the Prospectus Regulation. This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding the partial buyback of a number of OCEANEs convertible bonds. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on 27 May 2020 under n° D.20-0503 and in Section 2 “Risk Factors” of the Company’s Amendment to the Universal Registration Document filed with the AMF on 22 December 2020 under n° D.20-0503-A01, which are available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2019 Annual Report on Form 20-F filed with the SEC on May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | Investors Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com PRESS RELATIONS | Media Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com Attachment GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

  • Globe Newswire

    GENFIT : Franc succès de l’opération d’aménagement des termes et de rachat partiel de la dette obligataire

    Approbation par 98,5% des actionnaires (quorum 23,36%) et par 100% des porteurs d’OCEANEs (quorum 70,88%) s’étant exprimés85,7 millions d’euros de dette convertible seront effacés, en ne mobilisant que 47,48 millions d’euros après les opérations de règlement-livraison du rachat partiel devant se tenir cette semaineExtension de la maturité jusqu’à 2025, offrant à GENFIT les moyens d’exécuter son nouveau plan stratégique Lille (France), Cambridge (Massachusetts, États-Unis), le 25 janvier 2021 – GENFIT (Nasdaq et Euronext: GNFT), société biopharmaceutique de phase avancée engagée dans l’amélioration de la vie des patients atteints de maladies hépatiques et métaboliques (la « Société »), annonce aujourd’hui les résultats du vote des actionnaires lors de l’assemblée générale extraordinaire qui s’est déroulée, sur deuxième convocation, ce lundi 25 janvier 2021 à 14h30 (heure de Paris) (l’ « Assemblée Générale Extraordinaire ») et du vote des porteurs des obligations à option de conversion et/ou d’échange en actions nouvelles et/ou existantes émises par la Société le 16 octobre 2017 (les « OCEANEs ») lors de l’assemblée des porteurs des OCEANEs qui s’est déroulée ce lundi 25 janvier 2021 à 17h30 (l’ « Assemblée des Porteurs »). L’ensemble des résolutions proposées par le Conseil d’Administration de la Société aux deux assemblées ont été adoptées à plus de 98,5 % des suffrages exprimés pour ce qui concerne l’Assemblée Générale Extraordinaire et à 100 % des suffrages exprimés pour ce qui concerne l’Assemblée des Porteurs. La Société peut ainsi procéder au rachat partiel de 2 895 260 OCEANEs que certains des porteurs d’OCEANEs se sont engagés auprès de la Société à lui vendre à terme, au prix de 16,40 euros (incluant les intérêts courus d’une valeur de 0,30 euros) (sur 6 081 081 OCEANEs initialement émises et en circulation) représentant un montant nominal de 85 699 696 euros, soit 47,6 % des OCEANES en circulation (sur un montant nominal total de 179 999 997,60 euros) pour un montant total cumulé de 47,48 millions d’euros (le « Rachat Partiel »). Les opérations de règlement livraison du Rachat Partiel devraient se dérouler d’ici le 29 janvier 2021. Les OCEANEs ainsi rachetées seront annulées par la Société. Pascal Prigent, Directeur Général de GENFIT, a déclaré : « Nous remercions nos actionnaires et les porteurs d’OCEANE pour leur soutien tout au long de ce processus qui acte, aujourd’hui, la modification des termes de nos obligations et qui se conclura, cette semaine, par le rachat partiel. Ainsi, GENFIT effacera près de 50% de sa dette obligataire, soit environ 85,7 millions d’euros, en dépensant seulement 47,48 millions d’euros dans le rachat partiel. Nous parvenons en outre à reporter la maturité du solde des OCEANEs à fin 2025, ce qui devrait nous apporter davantage de flexibilité pour valoriser nos futurs résultats de Phase 3 dans la PBC, en cas de succès, début 2023, de notre essai clinique ELATIVE™. Nos équipes sont désormais tournées vers l’avenir et déterminées à faire de l’année 2021 celle du rebond : la contrainte financière étant desserrée, nous retrouvons en effet notre pleine capacité d’action pour exécuter notre nouvelle stratégie. » Assemblée Générale Extraordinaire Toutes les résolutions ont été adoptées à une large majorité de plus de 98,5% des suffrages exprimés, en accord avec les recommandations du Conseil d’Administration. 9 068 366 actions ont été enregistrées sur un total de 38 813 943 actions ayant droit de vote sur un total de 38 858 617 actions, représentant un quorum de 23,36%. Le résultat du scrutin par résolution est disponible sur le site internet de la Société dans la rubrique Investisseurs & Médias (https://ir.genfit.com/fr/informations-financieres/assemblee-generale-des-actionnaires). Une rediffusion de l’Assemblée Générale Extraordinaire est disponible depuis notre site web Investisseurs https://ir.genfit.com/fr, dans la section « événements » et sur la page « Assemblée Générale des actionnaires », dans l’onglet « Données financières ». Assemblée des Porteurs Toutes les résolutions ont été adoptées à 100% des suffrages exprimés, en accord avec les recommandations du Conseil d’Administration. 4 310 607 OCEANEs ont été enregistrées sur un total de 6 081 081 OCEANEs, représentant un quorum de 70,88%. Le résultat du scrutin par résolution est disponible sur le site internet de la Société dans la rubrique Investisseurs & Médias (https://ir.genfit.com/fr/informations-financieres/assemblee-generale-des-actionnaires). Une rediffusion de l’Assemblée des Porteurs est disponible depuis notre site web Investisseurs https://ir.genfit.com/fr, dans la section « événements » et sur la page « Assemblée Générale des actionnaires », dans l’onglet « Données financières ». À PROPOS DE GENFIT GENFIT est une société biopharmaceutique avancée engagée dans l’amélioration de la vie des patients atteints de maladies cholestatiques et métaboliques chroniques du foie. GENFIT est pionnier dans le domaine de la découverte de médicaments basés sur les récepteurs nucléaires, fort d'une histoire riche et d'un solide héritage scientifique de près de deux décennies. GENFIT recrute actuellement des patients pour ELATIVE™, un essai clinique de Phase 3 évaluant elafibranor dans la cholangite biliaire primitive (« PBC »). Abordant la prise en charge clinique des patients atteints de maladies hépatiques à travers une approche intégrée, GENFIT développe également NIS4™, une technologie nouvelle de diagnostic visant à faciliter l’identification des patients atteints de NASH « à risque ». NIS4™ fait l’objet d’un accord de licence à la Société LabCorp® pour le développement et la commercialisation aux Etats-Unis et au Canada d’un test diagnostic moléculaire sanguin basé sur cette technologie. GENFIT est installée à Lille, Paris et Cambridge, MA (États-Unis). GENFIT est une société cotée sur le Nasdaq Global Select Market et sur le marché réglementé d’Euronext à Paris, Compartiment B (Nasdaq et Euronext : GNFT). www.genfit.fr AVERTISSEMENT Ce communiqué n’est pas une communication à caractère promotionnelle et ne constitue pas un prospectus au sens du Règlement Prospectus. Ce communiqué de presse contient des déclarations prospectives à propos de GENFIT, y compris au sens où l’entend le Private Securities Litigation Reform Act de 1995 et en particulier des déclarations prospectives relatives au rachat partiel de certaines OCEANEs. L’utilisation de certains mots, comme tels que « considérer », « envisager », « penser », « avoir pour objectif », « s’attendre à », « entendre », « devoir », « ambitionner », « estimer », « croire », « souhaiter », « pouvoir », « permettre », « viser », « encourager », « être confiant » ou, le cas échéant, la forme négative de ces mêmes termes, ou toute autre variante ou terminologie similaire. Bien que la Société considère que ses projections soient basées sur des hypothèses et attentes raisonnables de sa Direction Générale, ces déclarations prospectives peuvent être remises en cause par un certain nombre d’aléas et d’incertitudes connus ou inconnus, ce qui pourrait donner lieu à des résultats substantiellement différents de ceux décrits, induits ou anticipés dans lesdites déclarations prospectives. Ces aléas et incertitudes comprennent, parmi d’autres, les incertitudes inhérentes à la recherche et développement, y compris dans le domaine des biomarqueurs, au progrès et aux résultats des essais cliniques prévus et en cours, aux examens et autorisations d’autorités réglementaires concernant ses candidats-médicaments et solutions diagnostiques, à la fluctuation des devises, à la capacité de la Société à continuer à lever des fonds pour son développement, ainsi qu’à ceux développés au Chapitre 2 « Facteurs de risque et contrôle interne » du Document d’Enregistrement Universel 2019 de la Société déposé auprès de l’Autorité des marchés financiers (« AMF ») le 27 mai 2020 sous le numéro D.20-0503, ainsi qu’à la section 2 « Facteurs de risque » de de l’Amendement au Document d’Enregistrement Universel déposé auprès de l’AMF le 22 décembre 2020 sous le numéro D.20-0503-A01, disponibles sur les sites Internet de GENFIT (www.genfit.fr) et de l’AMF (www.amf-france.org) et à ceux développés dans les documents publics et rapports déposés auprès de la Securities and Exchange Commissions (« SEC ») américaine, y compris le Rapport Annuel Form 20-F déposé auprès de la SEC le 27 mai 2020. De plus, même si les résultats, la performance, la situation financière et la liquidité de la Société et le développement du secteur industriel dans lequel elle évolue sont en ligne avec de telles déclarations prospectives, elles ne sauraient être prédictives de résultats ou de développements dans le futur. Ces déclarations prospectives ne sont valables qu’à la date de publication de ce document. Sous réserve de la réglementation applicable, la Société ne prend aucun engagement de mise à jour ou de révision des informations contenues dans ce communiqué, que ce soit en raison de nouvelles informations, d’évènements futurs ou autres. CONTACT GENFIT GENFIT | Investisseurs Naomi EICHENBAUM – Relations Investisseurs | Tel : +1 (617) 714 5252 | investors@genfit.com RELATIONS PRESSE | Media Bruno ARABIAN – Ulysse Communication | Tel : 06 87 88 47 26 | barabian@ulysse-communication.com Hélène LAVIN – GENFIT | Tel : 03 20 16 40 00 | helene.lavin@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com Pièce jointe GENFIT : Franc succès de l’opération d’aménagement des termes et de rachat partiel de la dette obligataire

  • Globe Newswire

    GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021 and informs the OCEANEs holders of certain procedures for the Bondholders’ Meeting of January 25, 2021

    Lille, France; Cambridge, MA; January 13, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases (the “Company”), today announces the publication in the January 13, 2021 French Bulletin des Annonces Légales Obligatoires of its convening notice for the shareholders’ extraordinary general meeting to be held on second notice on Monday, January 25, 2021, at 2:30 p.m. (Paris time) (the “Extraordinary General Meeting”) and informs holders of its bonds convertible into new shares and/or exchangeable for existing shares issued by the Company on October 16, 2017 (the “OCEANEs”) of certain changes in certain of the participation and organization procedures for the meeting of the holders of the OCEANEs of January 25, 2021, at 5:30 p.m. (Paris time) (the “Bondholders’ Meeting”). Extraordinary General Meeting The extraordinary general meeting convened today could not validly deliberate given the absence of required quorum, which amounted to 20.63 %. As a reminder, the required quorum for the Extraordinary General Meeting to validly deliberate on second notice is 20%. In accordance with articles R.225-77 and R.225-79 of the French Code de commerce, voting cards sent to the Company, electronic votes and proxies given to the shareholders meeting on first convening remain valid for the Extraordinary Shareholders Meeting on second notice called on January 25, 2021, at 2:30 p.m. to vote on the same agenda, as long as the securities voted remain in the respective shareholders’ accounts. The shareholders may still send their proxy forms or vote by post until January 21, 2021 at midnight (Paris time) and will be able to vote electronically on Votaccess platform starting January 14, 2021 and until January 24, 2021 at 3 p.m. (Paris time). In accordance with the provisions of Article 4 of Ordinance no. 2020-321 of March 25, 2020, which application period has been extended and terms have been modified by the Ordinance no. 2020-1497 of December 2, 2020, and the provisions of the decree no. 2020-1614 of December 18, 2020 extending and modifying decree n° 2020-418 of April 10, 2020 specifying the procedures for holding meetings behind closed doors (the “Decree”), the Extraordinary General Meeting will be held behind closed doors at the Company’s headquarters located Parc Eurasanté, 885 avenue Eugène Avinée Loos, 59120, France, with the same agenda as the January 13, 2021 shareholders extraordinary general meeting. The resolutions that were proposed to the January 13, 2021 shareholders extraordinary general meeting remain unchanged. The second part of the second convening notice (avis) published on January 13, 2021 French Bulletin des Annonces Légales Obligatoires no. 6 and available in the Investors & Media section of the Company’s website (https://ir.genfit.com/financial-information/shareholders-meeting) outlines the procedures by which shareholders may participate in the Extraordinary General Meeting notwithstanding the exceptional measures required in order to comply with regulatory constraints and ensure the health and safety of everyone. The Extraordinary General Meeting will be chaired by Mr. Jean-François Mouney, Chairman of the Board of Directors. Given the current pandemic and in accordance with the provisions of the Decree, the Company has appointed as observers (scrutateurs) of the Extraordinary General Meeting: Biotech Avenir and University of Lille, which have each accepted this appointment. A live audio broadcast of the Extraordinary General Meeting will be available on the Company’s website (https://ir.genfit.com) and a replay will be available on the Investors section of our website (https://ir.genfit.com) under the “Events” section and on the “Shareholders Meeting” page under “Financials”, as soon as possible at the end of the Extraordinary General Meeting and at the latest before the end of the fifth business day after such Extraordinary General Meeting. The French live broadcast will be accessible by calling +1 212 999 6659 (U.S.), +44 (0) 33 0551 0200 (UK) or +1 212 999 6659 (France) five minutes prior to the start time (Password: GENFIT). Bondholders’ Meeting Bondholders’ Meeting Participation Following the publication of the Decree, the Company informs that the procedures for participation in the Bondholders’ Meeting indicated in this press release (proxy representation, written questions, composition of the Committee and broadcast details) supplement those set out in the notice (avis) published in the Bulletins des Annonces Légales Obligatoires, no. 151 dated December 16, 2020. Due to the ongoing COVID-19 pandemic and in accordance with emergency measures imposed by the French government, the Board of Directors of the Company has decided that the Bondholders’ Meeting will be conducted behind closed doors at the Company’s headquarters located at Parc Eurasanté, 885 Avenue Eugène Avinée, Loos (59120), France, without the physical presence of the holders of the OCEANEs and others who are usually entitled to attend. Proxy representation at the Bondholders’ Meeting In accordance with the Decree, an OCEANE holder who has chosen to be represented by a proxy of its choice must notify its appointment to BNP Paribas Securities Services, and may also revoke it until the fourth day preceding the Bondholders’ Meeting, i.e. no later than Thursday, January 21, 2021, at midnight, Paris time. The proxy holder must send its voting instructions for the exercise of its proxy as a scanned copy of the voting form, to BNP Paribas Securities Services, by e-mail to the following address: paris.bp2s.france.cts.mandats@bnpparibas.com. The form must include the first and last name and address of the representative, the words “As a representative”, and must be dated and signed. The voting instructions are indicated in the “Voting Form”. The proxy holder must attach a copy of his proof of identity and, where applicable, a power of attorney of the legal person he represents. In accordance with the Decree and in order to be taken into account, the electronic message must be received by BNP Securities Services no later than the fourth day preceding the date of the Extraordinary General Meeting, i.e. Thursday, January 21, 2021, at midnight, Paris time. In accordance with the provisions of the Decree, each OCEANE holder who has already voted by post, given proxy to the chairman of the Bondholders’ Meeting, or given proxy to a third party may choose another means of participation in the Bondholders’ Meeting provided that the new instruction issued by this holder reaches the Company (i) according to the terms and deadlines specified in this press release regarding the proxies given to third parties, and (ii) according to the legal terms and deadlines as specified in the notice of the Bondholders’ Meeting available on the Company's website for votes by post or proxies to the chairman for the Bondholders’ Meeting. Their initial instructions will then be revoked. § Written questions at the Bondholders’ Meeting The holders of OCEANEs are invited to send their written questions to the Company at the latest until the end of the second business day preceding the date of the Bondholders’ Meeting, i.e. January 23, 2021. The answers to these questions will be published on the Company’s website as soon as possible at the end of the Bondholders’ Meeting, and at the latest before the end of the fifth business day from the date of such Bondholders’ Meeting. § Composition of the committee of the Bondholders’ Meeting The Bondholders’ Meeting will be chaired by Mr. Edouard Narboux, Aether Financial Services, representative of the holders of the OCEANEs. Given the current pandemic and in accordance with the provisions of the Decree, the Company informs that it has appointed as observers (scrutateurs) of the Bondholders’ Meeting: Syquant Capital and Polar Capital, which have each accepted this appointment. § Bondholders’ Meeting broadcast details A live audio broadcast of the Bondholders’ Meeting will be available on the Company’s website (https://ir.genfit.com) and a replay will be available at the Investors section of our website (https://ir.genfit.com) under the “Events” section and on the “Shareholders Meeting” page under “Financials”, as soon as possible at the end of the Bondholders’ Meeting and at the latest before the end of the fifth business day after such Bondholders’ Meeting. The live broadcast will be accessible by calling +1 212 999 6659 (U.S.), +44 (0) 33 0551 0200 (UK) or +1 212 999 6659 (France) five minutes prior to the start time (Password: GENFIT). ABOUT GENFIT GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with cholestatic and metabolic chronic liver diseases. GENFIT is a pioneer in the field of nuclear receptor-based drug discovery, with a rich history and strong scientific heritage spanning more than two decades. GENFIT is currently enrolling in ELATIVE™, a Phase 3 clinical trial evaluating elafibranor in patients with Primary Biliary Cholangitis (PBC). As part of GENFIT’s comprehensive approach to clinical management of patients with liver disease, the Company is also developing NIS4™, a new, non-invasive blood-based diagnostic technology which could enable easier identification of patients with at-risk NASH. NIS4™ technology has been licensed to LabCorp in the U.S. and Canada for the development and commercialization of a blood-based molecular diagnostic test powered by NIS4™ technology. GENFIT has facilities in Lille and Paris, France, and Cambridge, MA, USA. GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). www.genfit.com FORWARD LOOKING STATEMENTS This press release is not an advertisement and does not constitute a prospectus for the purpose of the Prospectus Regulation. This press release contains certain forward-looking statements with respect to GENFIT, including those within the meaning of the Private Securities Litigation Reform Act of 1995, with respect to GENFIT, including statements regarding our capacity to renegotiate the terms of our OCEANEs convertible bonds and that the final terms of this proposal will be approved by the shareholders’ general meeting and general meeting of OCEANEs holders. The use of certain words, including “consider”, “contemplate”, “think”, “aim”, “expect”, “understand”, “should”, “aspire”, “estimate”, “believe”, “wish”, “may”, “could”, “allow”, “seek”, “encourage” or “have confidence” or (as the case may be) the negative forms of such terms or any other variant of such terms or other terms similar to them in meaning is intended to identify forward-looking statements. Although the Company believes its projections are based on reasonable expectations and assumptions of the Company’s management, these forward-looking statements are subject to numerous known and unknown risks and uncertainties, which could cause actual results to differ materially from those expressed in, or implied or projected by, the forward-looking statements. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including in relation to safety, biomarkers, progression of, and results from, its ongoing and planned clinical trials, review and approvals by regulatory authorities of its drug and diagnostic candidates, exchange rate fluctuations and the Company’s continued ability to raise capital to fund its development, as well as those risks and uncertainties discussed or identified in the Company’s public filings with the AMF, including those listed in Chapter 2 “Main Risks and Uncertainties” of the Company’s 2019 Universal Registration Document filed with the AMF on 27 May 2020 under n° D.20-0503 and in Section 2 “Risk Factors” of the Company’s Amendment to the Universal Registration Document filed with the AMF on 22 December 2020 under n° D.20-0503-A01, which are available on the Company’s website (www.genfit.com) and on the website of the AMF (www.amf-france.org) and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”) including the Company’s 2019 Annual Report on Form 20-F filed with the SEC on May 27, 2020. In addition, even if the Company’s results, performance, financial condition and liquidity, and the development of the industry in which it operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These forward-looking statements speak only as of the date of publication of this document. Other than as required by applicable law, the Company does not undertake any obligation to update or revise any forward-looking information or statements, whether as a result of new information, future events or otherwise. CONTACT GENFIT | Investors Naomi EICHENBAUM – Investor Relations | Tel: +1 (617) 714 5252 | investors@genfit.com PRESS RELATIONS | Media Hélène LAVIN – Press relations | Tel: +333 2016 4000 | helene.lavin@genfit.com GENFIT | 885 Avenue Eugène Avinée, 59120 Loos - FRANCE | +333 2016 4000 | www.genfit.com Attachment GENFIT announces that its Extraordinary General Meeting on second notice will be held January 25, 2021